We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EQT icon
101
EQT Corp
EQT
$31B
$1.16M 0.32%
18,290
-8,800
-32% -$516K
STX icon
102
Seagate
STX
$178B
$1.14M 0.31%
+2,900
New +$1.11M
PBR.A icon
103
Petrobras Class A
PBR.A
$103B
$1.11M 0.31%
59,400
+4,200
+8% +$62.2K
WDC icon
104
Western Digital
WDC
$164B
$1.11M 0.31%
+4,100
New +$1.07M
FERG icon
105
Ferguson
FERG
$45B
$1.09M 0.3%
4,673
-2,300
-33% -$560K
APG icon
106
APi Group
APG
$17.4B
$1.08M 0.3%
26,658
-4,300
-14% -$182K
TVTX icon
107
Travere Therapeutics
TVTX
$5.27B
$1.08M 0.3%
+36,325
New +$1.09M
WDAY icon
108
Workday
WDAY
$35.8B
$1.08M 0.3%
8,286
+1,800
+28% +$286K
PTC icon
109
PTC
PTC
$14.4B
$1.06M 0.29%
7,474
+1,100
+17% +$174K
GEV icon
110
GE Vernova
GEV
$284B
$1.06M 0.29%
1,218
-550
-31% -$429K
NKTR icon
111
Nektar Therapeutics
NKTR
$2.31B
$1.05M 0.29%
14,555
+2,806
+24% +$160K
AGX icon
112
Argan
AGX
$7.73B
$1.03M 0.29%
1,896
– –
NEE icon
113
NextEra Energy
NEE
$185B
$1.03M 0.28%
11,085
-8,200
-43% -$729K
DASH icon
114
DoorDash
DASH
$80.2B
$1.01M 0.28%
+6,710
New +$1.24M
XEL icon
115
Xcel Energy
XEL
$49.2B
$998K 0.28%
12,558
+4,500
+56% +$353K
META icon
116
Meta Platforms (Facebook)
META
$1.64T
$997K 0.28%
1,742
-820
-32% -$526K
TLN
117
Talen Energy Corp
TLN
$17.8B
$995K 0.27%
3,118
-370
-11% -$131K
AMRZ
118
Amrize Ltd
AMRZ
$27.5B
$956K 0.26%
17,068
-16,400
-49% -$940K
RDDT icon
119
Reddit
RDDT
$34.9B
$929K 0.26%
6,900
+1,600
+30% +$272K
UTHR icon
120
United Therapeutics
UTHR
$22.7B
$898K 0.25%
1,514
-816
-35% -$406K
MMM icon
121
3M
MMM
$83.4B
$893K 0.25%
6,150
+2,200
+56% +$350K
UNP icon
122
Union Pacific
UNP
$179B
$888K 0.25%
3,658
-4,400
-55% -$1.08M
AVTX icon
123
Avalo Therapeutics
AVTX
$1.02B
$875K 0.24%
58,622
-37,009
-39% -$579K
CPNG icon
124
Coupang
CPNG
$29.8B
$869K 0.24%
46,036
+21,244
+86% +$416K
CLF icon
125
Cleveland-Cliffs
CLF
$5.29B
$866K 0.24%
102,474
-16,100
-14% -$184K
3 4
5
6 7

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.